|
"hsieh t y"的相关文件
显示项目 21-45 / 138 (共6页)
1 2 3 4 5 6 > >>
每页显示[10|25|50]项目
| 臺大學術典藏 |
2022-01-25T03:25:12Z |
Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients
|
Su T.-H.; Hu T.-H.; Chen C.-Y.; Huang Y.-H.; Chuang W.-L.; Lin C.-C.; Wang C.-C.; Su W.-W.; Chen M.-Y.; Peng C.-Y.; Chien R.-N.; Huang Y.-W.; Wang H.-Y.; Lin C.-L.; Yang S.-S.; Chen T.-M.; Mo L.-R.; Hsu S.-J.; Tseng K.-C.; Hsieh T.-Y.; Suk F.-M.; Hu C.-T.; Bair M.-J.; Liang C.-C.; Lei Y.-C.; Tseng T.-C.; CHI-LING CHEN; Kao J.-H.; the C-TEAM study group; the Taiwan Liver Diseases Consortium |
| 臺大學術典藏 |
2022-01-24T09:32:20Z |
Comparison of a 6-month course peginterferon α-2b plus ribavirin and interferon α-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan
|
Lee S.-D.; Yu M.-L.; Cheng P.-N.; Lai M.-Y.; Chao Y.-C.; Hwang S.-J.; Chang W.-Y.; Chang T.-T.; Hsieh T.-Y.; CHUN-JEN LIU; Chen D.-S. |
| 臺大學術典藏 |
2022-01-24T09:32:16Z |
Interferon α-2b with and without ribavirin in the treatment of hepatitis B e antigen-positive chronic hepatitis B: A randomized study
|
CHUN-JEN LIU; Lai M.-Y.; Chao Y.-C.; Liao L.-Y.; Yang S.-S.; Hsiao T.-J.; Hsieh T.-Y.; Lin C.-L.; Hu J.-T.; Chen C.-L.; Chen P.-J.; Kao J.-H.; Chen D.-S. |
| 臺大學術典藏 |
2022-01-24T09:31:13Z |
Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis
|
Liu C.-H.; Shih Y.-L.; Yang S.-S.; Lin C.-L.; Fang Y.-J.; Cheng P.-N.; Chen C.-Y.; Peng C.-Y.; Hsieh T.-Y.; Chiu Y.-C.; Su T.-H.; CHUN-JEN LIU; Yang H.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:11Z |
Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment
|
Liu C.-H.; Chen C.-Y.; Su W.-W.; Tseng K.-C.; Lo C.-C.; CHUN-JEN LIU; Chen J.-J.; Peng C.-Y.; Shih Y.-L.; Yang S.-S.; Huang C.-S.; Huang K.-J.; Chang C.-Y.; Tsai M.-C.; Kao W.-Y.; Fang Y.-J.; Chen P.-Y.; Su P.-Y.; Tseng C.-W.; Huang J.-J.; Lee P.-L.; Lai H.-C.; Hsieh T.-Y.; Chang C.-H.; Huang Y.-J.; Lee F.-J.; Chang C.-C.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:00Z |
Impact of Sofosbuvir-Based Direct-Acting Antivirals on Renal Function in Chronic Hepatitis C Patients With Impaired Renal Function: A Large Cohort Study From the Nationwide HCV Registry Program (TACR)
|
Huang C.-F.; Tseng K.-C.; Cheng P.-N.; Hung C.-H.; Lo C.-C.; Peng C.-Y.; Bair M.-J.; Yeh M.-L.; Chen C.-H.; Lee P.-L.; Lin C.-Y.; Kuo H.-T.; Chen C.-T.; Yang C.-C.; Huang J.-F.; Tai C.-M.; Hu J.-T.; Lin C.-L.; Su W.-W.; Tsai W.-L.; Huang Y.-H.; Cheng C.-Y.; Lin C.-L.; Wang C.-C.; Yang S.-S.; Mo L.-R.; Chen G.-Y.; Chang C.-C.; Wang S.-J.; Huang C.-S.; Hsieh T.-Y.; Lin C.-W.; Lee T.-H.; Chong L.-W.; Huang C.-W.; Chang S.-N.; Tsai M.-C.; Hsu S.-J.; Kao J.-H.; CHUN-JEN LIU; Liu C.-H.; Lin H.-C.; Lee M.-H.; Tsai P.-C.; Dai C.-Y.; Chuang W.-L.; Chen C.-Y.; Yu M.-L. |
| 臺大學術典藏 |
2022-01-24T09:30:59Z |
Sofosbuvir/Velpatasvir for Hepatitis?C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan
|
Cheng P.-N.; Mo L.-R.; Chen C.-T.; Chen C.-Y.; Huang C.-F.; Kuo H.-T.; Lo C.-C.; Tseng K.-C.; Huang Y.-H.; Tai C.-M.; Peng C.-Y.; Bair M.-J.; Chen C.-H.; Yeh M.-L.; Lin C.-L.; Lin C.-Y.; Lee P.-L.; Chong L.-W.; Hung C.-H.; Chang T.S.; Huang J.-F.; Yang C.-C.; Hu J.-T.; Lin C.-W.; Wang C.-C.; Su W.-W.; Hsieh T.-Y.; Lin C.-L.; Tsai W.-L.; Lee T.-H.; Chen G.-Y.; Wang S.-J.; Chang C.-C.; Yang S.-S.; Wu W.-C.; Huang C.-S.; Chou K.-H.; Kao C.-N.; Tsai P.-C.; Liu C.-H.; Lee M.-H.; Cheng C.-Y.; Tsai M.-C.; CHUN-JEN LIU; Dai C.-Y.; Lin H.-C.; Kao J.-H.; Chuang W.-L.; Yu M.-L.; TACR investigators |
| 臺大學術典藏 |
2022-01-24T09:30:58Z |
Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan
|
Liu C.-H.; Chen P.-Y.; Chen J.-J.; Lo C.-C.; Su W.-W.; Tseng K.-C.; CHUN-JEN LIU; Huang C.-S.; Huang K.-J.; Yang S.-S.; Peng C.-Y.; Tsai M.-C.; Kao W.-Y.; Chang C.-Y.; Shih Y.-L.; Fang Y.-J.; Chen C.-Y.; Lee P.-L.; Huang J.-J.; Su P.-Y.; Tseng C.-W.; Hung C.-C.; Chang C.-H.; Huang Y.-J.; Lai H.-C.; Chang C.-C.; Lee F.-J.; Hsieh T.?Y.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:30:57Z |
Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan
|
Chen C.-Y.; Huang C.-F.; Cheng P.-N.; Tseng K.-C.; Lo C.-C.; Kuo H.-T.; Huang Y.-H.; Tai C.-M.; Peng C.-Y.; Bair M.-J.; Chen C.-H.; Yeh M.-L.; Lin C.-L.; Lin C.-Y.; Lee P.-L.; Chong L.-W.; Hung C.-H.; Huang J.-F.; Yang C.-C.; Hu J.-T.; Lin C.-W.; Chen C.-T.; Wang C.-C.; Su W.-W.; Hsieh T.-Y.; Lin C.-L.; Tsai W.-L.; Lee T.-H.; Chen G.-Y.; Wang S.-J.; Chang C.-C.; Mo L.-R.; Yang S.-S.; Wu W.-C.; Huang C.-S.; Hsiung C.-K.; Kao C.-N.; Tsai P.-C.; Liu C.-H.; Lee M.-H.; CHUN-JEN LIU; Dai C.-Y.; Kao J.-H.; Chuang W.-L.; Lin H.-C.; Yu M.-L. |
| 臺大學術典藏 |
2022-01-24T09:30:53Z |
Sofosbuvir/velpatasvir plus ribavirin for child-pugh b and child-pugh c hepatitis c virus-related cirrhosis
|
Liu C.-H.; Chen C.-Y.; Su W.-W.; CHUN-JEN LIU; Lo C.-C.; Huang K.-J.; Chen J.-J.; Tseng K.-C.; Chang C.-Y.; Peng C.-Y.; Shih Y.-L.; Huang C.-S.; Kao W.-Y.; Yang S.-S.; Tsai M.-C.; Wu J.-H.; Chen P.-Y.; Su P.-Y.; Hwang J.-J.; Fang Y.-J.; Lee P.-L.; Tseng C.-W.; Lee F.-J.; Lai H.-C.; Hsieh T.-Y.; Chang C.-C.; Chang C.-H.; Huang Y.-J.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:30:52Z |
Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan
|
Huang C.-F.; Kuo H.-T.; Chang T.-S.; Lo C.-C.; Hung C.-H.; Huang C.-W.; Chong L.-W.; Cheng P.-N.; Yeh M.-L.; Peng C.-Y.; Cheng C.-Y.; Huang J.-F.; Bair M.-J.; Lin C.-L.; Yang C.-C.; Wang S.-J.; Hsieh T.-Y.; Lee T.-H.; Lee P.-L.; Wu W.-C.; Lin C.-L.; Su W.-W.; Yang S.-S.; Wang C.-C.; Hu J.-T.; Mo L.-R.; Chen C.-T.; Huang Y.-H.; Chang C.-C.; Huang C.-S.; Chen G.-Y.; Kao C.-N.; Tai C.-M.; CHUN-JEN LIU; Lee M.-H.; Tsai P.-C.; Dai C.-Y.; Kao J.-H.; Lin H.-C.; Chuang W.-L.; Chen C.-Y.; Tseng K.-C.; Yu M.-L. |
| 臺大學術典藏 |
2022-01-11T06:49:25Z |
Recommendations for psoriatic arthritis management: A joint position paper of the Taiwan Rheumatology Association and the Taiwanese Association for Psoriasis and Skin Immunology
|
Tsai T.-F.; Hsieh T.-Y.; Chi C.-C.; Chou C.-T.; Hsieh L.-F.; Chen H.-H.; Hui R.C.-Y.; Lee C.-H.; Liu C.-H.; Liu H.-C.; Yeo K.-J.; Chen C.-H.; Chen H.-A.; Chen Y.-C.; Chen Y.-J.; HSIEN-YI CHIU; Ho J.-C.; Huang Y.-H.; Lai P.-J.; Lee W.-R.; Liao H.-T.; Lin S.-H.; Tseng J.-C.; Wang T.-S.; Wu N.-L.; Yang D.-H.; Tsai W.-C.; Wei J.C.-C.; Taiwan Rheumatology Association (TRA); the Taiwanese Association for Psoriasis; Skin Immunology (TAPSI) |
| 臺大學術典藏 |
2022-01-11T06:49:24Z |
Predictors of hepatitis B and C virus reactivation in patients with psoriasis treated with biologic agents: a 9-year multicenter cohort study
|
HSIEN-YI CHIU; Chiu Y.-M.; Chang Liao N.-F.; Chi C.-C.; Tsai T.-F.; Hsieh C.-Y.; Hsieh T.-Y.; Lai K.-L.; Chiu T.-M.; Wu N.-L.; Hui R.C.-Y.; Lee C.-N.; Wang T.-S.; Chen P.-H.; Yang C.-C.; Huang Y.-H. |
| 國立成功大學 |
2022 |
2022 Taiwanese Dermatological Association (TDA), Taiwanese Association for Psoriasis and Skin Immunology (TAPSI), and Taiwan Society of cardiology (TSOC) joint consensus recommendations for the management of psoriatic disease with attention to cardiovascu
|
Chi, Chi C.-C.;Wu, Y.-W.;Chao, T.-H.;Chen, Chen C.-C.;Chen, Y.-J.;Cheng, H.-M.;Chiu, H.-Y.;Chiu, Y.-W.;Chung, W.-H.;Hsieh, T.-Y.;Huang, P.-H.;Huang, Y.-H.;Lin, S.-H.;Lin, T.-H.;Ueng, K.-C.;Wang, C.-C.;Wang, Y.-C.;Wu, N.-L.;Jia-Yin, Hou C.;Tsai, Tsai T.-F. |
| 國立成功大學 |
2022 |
Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4–6 infection: Real-world evidence from a nationwide registry in Taiwan
|
Lo, C.-C.;Huang, C.-F.;Cheng, P.-N.;Tseng, K.-C.;Chen, Chen C.-Y.;Kuo, H.-T.;Huang, Y.-H.;Tai, C.-M.;Peng, C.-Y.;Bair, M.-J.;Chen, Chen C.-H.;Yeh, M.-L.;Lin, C.-L.;Lin, C.-Y.;Lee, P.-L.;Chong, L.-W.;Hung, C.-H.;Chang, T.S.;Huang, J.-F.;Yang, C.-C.;Hu, J.-T.;Lin, C.-W.;Chen, Chen C.-T.;Wang, C.-C.;Su, W.-W.;Hsieh, T.-Y.;Lin, C.-L.;Tsai, W.-L.;Lee, T.-H.;Chen, G.-Y.;Wang, S.-J.;Chang, Chang C.-C.;Mo, L.-R.;Yang, S.-S.;Wu, Wu W.-C.;Huang, C.-S.;Hsiung, C.-K.;Kao, C.-N.;Tsai, P.-C.;Liu, C.-H.;Lee, M.-H.;Liu, C.-J.;Dai, C.-Y.;Chuang, W.-L.;Lin, H.-C.;Kao, J.-H.;Yu, M.-L.;investigators, TACR |
| 國立成功大學 |
2022 |
Impact of Sofosbuvir-Based Direct-Acting Antivirals on Renal Function in Chronic Hepatitis C Patients With Impaired Renal Function: A Large Cohort Study From the Nationwide HCV Registry Program (TACR)
|
Huang, C.-F.;Tseng, K.-C.;Cheng, P.-N.;Hung, C.-H.;Lo, C.-C.;Peng, C.-Y.;Bair, M.-J.;Yeh, M.-L.;Chen, Chen C.-H.;Lee, P.-L.;Lin, C.-Y.;Kuo, H.-T.;Chen, Chen C.-T.;Yang, C.-C.;Huang, J.-F.;Tai, C.-M.;Hu, J.-T.;Lin, C.-L.;Su, W.-W.;Tsai, W.-L.;Huang, Y.-H.;Cheng, Cheng C.-Y.;Lin, C.-L.;Wang, C.-C.;Yang, S.-S.;Mo, L.-R.;Chen, G.-Y.;Chang, Chang C.-C.;Wang, S.-J.;Huang, C.-S.;Hsieh, T.-Y.;Lin, C.-W.;Lee, T.-H.;Chong, L.-W.;Huang, C.-W.;Chang, S.-N.;Tsai, M.-C.;Hsu, S.-J.;Kao, J.-H.;Liu, C.-J.;Liu, C.-H.;Lin, H.-C.;Lee, M.-H.;Tsai, P.-C.;Dai, C.-Y.;Chuang, W.-L.;Chen, Chen C.-Y.;Yu, M.-L. |
| 國立成功大學 |
2022 |
Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-Acting Antivirals
|
Chen, Y.-C.;Chang, T.-S.;Chen, Chen C.-H.;Cheng, P.-N.;Lo, C.-C.;Mo, L.-R.;Chen, Chen C.-T.;Huang, C.-F.;Kuo, H.-T.;Huang, Y.-H.;Tai, C.-M.;Peng, C.-Y.;Bair, M.-J.;Yeh, M.-L.;Lin, C.-L.;Lin, C.-Y.;Lee, P.-L.;Chong, L.-W.;Hung, C.-H.;Huang, J.-F.;Yang, C.-C.;Hu, J.-T.;Lin, C.-W.;Wang, C.-C.;Su, W.-W.;Hsieh, T.-Y.;Lin, C.-L.;Tsai, W.-L.;Lee, T.-H.;Chen, G.-Y.;Wang, S.-J.;Chang, Chang C.-C.;Yang, S.-S.;Wu, Wu W.-C.;Huang, C.-S.;Hsiung, C.-K.;Kao, C.-N.;Tsai, P.-C.;Liu, C.-H.;Lee, M.-H.;Dai, C.-Y.;Kao, J.-H.;Chuang, W.-L.;Lin, H.-C.;Chen, Chen C.-Y.;Tseng, K.-C.;Yu, M.-L.;investigators, on behalf of TACR |
| 國立成功大學 |
2022 |
Sofosbuvir/Velpatasvir for Hepatitis�C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan
|
Cheng, P.-N.;Mo, L.-R.;Chen, Chen C.-T.;Chen, Chen C.-Y.;Huang, C.-F.;Kuo, H.-T.;Lo, C.-C.;Tseng, K.-C.;Huang, Y.-H.;Tai, C.-M.;Peng, C.-Y.;Bair, M.-J.;Chen, Chen C.-H.;Yeh, M.-L.;Lin, C.-L.;Lin, C.-Y.;Lee, P.-L.;Chong, L.-W.;Hung, C.-H.;Chang, T.S.;Huang, J.-F.;Yang, C.-C.;Hu, J.-T.;Lin, C.-W.;Wang, C.-C.;Su, W.-W.;Hsieh, T.-Y.;Lin, C.-L.;Tsai, W.-L.;Lee, T.-H.;Chen, G.-Y.;Wang, S.-J.;Chang, Chang C.-C.;Yang, S.-S.;Wu, Wu W.-C.;Huang, C.-S.;Chou, K.-H.;Kao, C.-N.;Tsai, P.-C.;Liu, C.-H.;Lee, M.-H.;Cheng, Cheng C.-Y.;Tsai, M.-C.;Liu, C.-J.;Dai, C.-Y.;Lin, H.-C.;Kao, J.-H.;Chuang, W.-L.;Yu, M.-L.;investigators, TACR |
| 臺大學術典藏 |
2021-10-28T07:11:18Z |
Recommendations for psoriatic arthritis management: A joint position paper of the Taiwan Rheumatology Association and the Taiwanese Association for Psoriasis and Skin Immunology
|
TSEN-FANG TSAI; Hsieh T.-Y.; Chi C.-C.; Chou C.-T.; Hsieh L.-F.; Chen H.-H.; Hui R.C.-Y.; Lee C.-H.; Liu C.-H.; Liu H.-C.; Yeo K.-J.; Chen C.-H.; Chen H.-A.; Chen Y.-C.; Chen Y.-J.; Chiu H.-Y.; Ho J.-C.; Huang Y.-H.; Lai P.-J.; Lee W.-R.; Liao H.-T.; Lin S.-H.; Tseng J.-C.; Wang T.-S.; Wu N.-L.; Yang D.-H.; Tsai W.-C.; Wei J.C.-C.; Taiwan Rheumatology Association (TRA); the Taiwanese Association for Psoriasis; Skin Immunology (TAPSI) |
| 臺大學術典藏 |
2021-10-28T07:11:16Z |
Predictors of hepatitis B and C virus reactivation in patients with psoriasis treated with biologic agents: a 9-year multicenter cohort study
|
Chiu H.-Y.; Chiu Y.-M.; Chang Liao N.-F.; Chi C.-C.; TSEN-FANG TSAI; Hsieh C.-Y.; Hsieh T.-Y.; Lai K.-L.; Chiu T.-M.; Wu N.-L.; Hui R.C.-Y.; Lee C.-N.; Wang T.-S.; Chen P.-H.; Yang C.-C.; Huang Y.-H. |
| 臺大學術典藏 |
2021-09-04T06:18:58Z |
Interferon α-2b with and without ribavirin in the treatment of hepatitis B e antigen-positive chronic hepatitis B: A randomized study
|
Liu C.-J.; Lai M.-Y.; Chao Y.-C.; Liao L.-Y.; Yang S.-S.; Hsiao T.-J.; Hsieh T.-Y.; Lin C.-L.; Hu J.-T.; Chen C.-L.; Chen P.-J.; JIA-HORNG KAO; Chen D.-S. |
| 臺大學術典藏 |
2021-09-04T06:11:54Z |
Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir
|
Wang C.-C.; Tseng K.-C.; Peng C.-Y.; Hsieh T.-Y.; Lin C.-L.; Su T.-H.; Tseng T.-C.; Hsu C.-S.; Lin H.H.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:42Z |
Higher adherence with 3-year entecavir treatment than lamivudine or telbivudine in treatment-na?ve Taiwanese patients with chronic hepatitis B
|
Chien R.-N.; Peng C.-Y.; JIA-HORNG KAO; Hu T.-H.; Lin C.-C.; Hu C.-T.; Chen C.-Y.; Hsieh T.-Y.; Lin H.-C.; Chuang W.-L. |
| 臺大學術典藏 |
2021-09-04T06:11:28Z |
HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients
|
Peng C.-Y.; Hsieh T.-C.; Hsieh T.-Y.; Tseng K.-C.; Lin C.-L.; Su T.-H.; Tseng T.-C.; Lin H.H.; Wang C.-C.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:18Z |
Efficacy and resistance to telbivudine treatment in chronic hepatitis B patients with favorable predictors: a multicenter study in Taiwan
|
Wang C.-C.; Lin C.-L.; Hsieh T.-Y.; Tseng K.-C.; Peng C.-Y.; Su T.-H.; Yang S.-S.; Hsu Y.-C.; Chen T.-M.; JIA-HORNG KAO |
显示项目 21-45 / 138 (共6页)
1 2 3 4 5 6 > >>
每页显示[10|25|50]项目
|
